RIBOGALPLEX
LIVE

Serial Number

99620295

Owner

Suzhou Ribo Life Science Co., Ltd.

Attorney

Zhi Dong

Filing Date

Jan 28, 2026

Add to watchlist:

No watchlists yet
View on USPTO

RIBOGALPLEX Trademark

Serial Number: 99620295

RIBOGALPLEX is a trademark filed by Suzhou Ribo Life Science Co., Ltd. on January 28, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Suzhou Ribo Life Science Co., Ltd. (10 trademarks)

168 Yuanfeng Road,

Entity Type: 16

Trademark Details

Filing Date

January 28, 2026

Registration Date

Not Registered

Published for Opposition

June 23, 2026

Goods & Services

technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; research and development services of new pharmaceutical products; research and development in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design

medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; Biological preparations for use in cell cultures for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; Pharmaceutical products for the treatment of cancer; anti-cancer preparations; Biopharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment and prevention of cancer; tumor suppressing agents; Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; Anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic foods and beverages adapted for medical use; depuratives for the body; pesticides; Medical dressings; Composite materials for dental and dental technical purposes

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
May 27, 2026 CNSA
ASSIGNED TO EXAMINER
May 27, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 20, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 28, 2026 MAFR
NEW APPLICATION ENTERED
Jan 28, 2026 NWAP